About Us Our Work Employment News & Events
MITRE Remote Access for MITRE Staff and Partners Site Map




Follow Us:

Visit MITRE on Facebook
Visit MITRE on Twitter
Visit MITRE on Linkedin
Visit MITRE on YouTube
View MITRE's RSS Feeds
View MITRE's Mobile Apps

Home > News & Events > MITRE Publications > Envision >
Optical Coherence Tomography:

OPTICAL COHERENCE TOMOGRAPHY:
DETECTING DISEASE EARLY THROUGH
RETINAL IMAGING

By Salim Semy

SUMMARY: Your eyes are said to be the window to your soul. For physicians, they soon may also become windows into your health. Using high-detail retinal imaging, clinicians will be able to scan your eye for early signs of chronic disease.

The Telltale Eye

Early diagnosis of individuals with chronic disease is a global health goal because the sooner a physician can detect a disease in a patient, the better the prognosis. In the U.S. alone, more than 6 million people have diabetes without knowing it, according to a 2009 study. That study estimated the cost of undiagnosed type-2 diabetes in medical services and lost productivity to be $18 billion a year.

Eye researchers have observed that many chronic diseases, such as diabetes, hypertension, and cardiovascular and cerebrovascular conditions, leave telltale clues of their presence in the retina. By detecting these clues using novel retinal imaging technologies, physicians can treat the underlying diseases earlier, more successfully, and at a lower cost.

One such imaging technology is optical coherence tomography (OCT), which was introduced in the early 1990s. OCT scans a near-infrared laser beam multiple times across the retina (with no discomfort to the patient) and measures the depth and intensity of the reflected light, from which it forms a three-dimensional image of the retina at a micrometer resolution. These 3-D models allow clinicians to see features, such as individual retinal layers and the presence of macular fluid, that are invisible to the naked eye or to other imaging technologies.

The non-invasive and highly repeatable OCT procedure lends itself well to providing a fully automated screening process. With a simple, painless sweep of a laser, clinicians will be able to diagnose diseases that once would have escaped early detection. Using automated OCT scans and diagnoses, large populations could be screened for early signs of disease. Such an automated screening process would free up clinicians to focus on patients with critical needs.

Optical Coherence Tomography:

OCT Challenges

Taking best advantage of the diagnostic promise of OCT technology presents several challenges. First, for devices such as OCT to serve as standard disease screening tools, they must become more cost-effective, scalable, standardized, and accessible to patients.

Second, the cost and time needed for OCT imaging interpretation must be reduced. Because OCT images incorporate a rich amount of data, it would be impractical for clinicians to manually analyze the retinal images of large populations in search of signs of disease.

Third, clinicians will need to know which diseases leave behind which clues in the retina. This will be difficult because currently there is insufficient data to help researchers identify novel disease predictors.

If we can overcome these challenges, there is an opportunity to cost-effectively perform routine disease screening.

EyesFirst

To help develop OCT-based disease screening capabilities, MITRE is pursuing a research project called EyesFirst. The key goal of the project is to work with clinicians and biomedical researchers to advance the state of the art in OCT image analysis techniques to where it is possible to automatically detect early signs of multiple chronic diseases.

MITRE hopes to demonstrate the value of employing an open, standards-based architecture to develop analysis tools that will aid the clinician in interpreting OCT scans and double-checking diagnoses. With EyesFirst, clinicians could compare a patient's history of OCT images to assess disease severity and track disease progression. They could also create statistical models to help identify subtle deviations not visible to the human eye and to classify scans as being normal or diseased.

As a byproduct of the EyesFirst project, MITRE also hopes to establish a database of OCT retinal images tagged with medical history information (minus any personally identifying data). This database could enable correlations between retinal changes and the onset and progression of chronic disease, leading to the identification of novel disease predictors. Such a database will also allow for the validation of automated OCT analysis tools.

EyesFirst is an open-source project; MITRE will freely share our results (including data and OCT image analysis algorithms) with the scientific community. In this way, our ideas and findings can be verified, extended, and put into action.

Self-Service Disease Screening

As we develop faster, better, and cheaper OCT devices, as we discover new retinal predictors of disease, and as we refine automated diagnostic tools and processing algorithms, OCT technology may become a routine part of healthcare exams. Ultimately, there may be self-service kiosks at your local Wal-Mart, similar to today's blood pressure instruments, where shoppers can enter the kiosk, get their eyes scanned, and receive a printed report with the results of the analysis and any necessary prompt to contact a physician for a follow-up exam. Patients will gain more control over diagnostic procedures and over their healthcare data. The role of physicians will shift from diagnostic to therapeutic. OCT technology will be one more step in making our nation's healthcare system more effective and less costly.

Salim Semy

INSIDE VIEW

Salim Semy had his first glimpse into the trauma of vision loss while pursuing a master's degree in biomedical sciences at the Boston University Medical School through MITRE's graduate studies program. His thesis project concerned the design of a retinal prosthetic for patients that suffer from retinal degeneration, as in the case of retinitis pigmentosa and age-related macular degeneration. Semy brought back to MITRE the sobering facts he had learned about disease-based vision loss and began exploring how MITRE could invest its expertise in image processing into a solution. "Thirty percent of diabetics don't know that they have the disease. As a result, by the time they go to see an ophthalmologist, there's often already irreversible vision loss. By finding and fielding a new diagnostic tool, we could save a lot of people's eyesight."

Related Information

Articles and News

Technical Papers and Presentations

Websites

 

For more information, please contact Salim Semy using the employee directory.


Page last updated: February 22, 2012   |   Top of page

Homeland Security Center Center for Enterprise Modernization Command, Control, Communications and Intelligence Center Center for Advanced Aviation System Development

 
 
 

Solutions That Make a Difference.®
Copyright © 1997-2013, The MITRE Corporation. All rights reserved.
MITRE is a registered trademark of The MITRE Corporation.
Material on this site may be copied and distributed with permission only.

IDG's Computerworld Names MITRE a "Best Place to Work in IT" for Eighth Straight Year The Boston Globe Ranks MITRE Number 6 Top Place to Work Fast Company Names MITRE One of the "World's 50 Most Innovative Companies"
 

Privacy Policy | Contact Us